Servier India, a subsidiary of French pharmaceutical company Servier Group, has launched a biomarker testing initiative with India’s genomic laboratories MedGenome and Strand Life Sciences, for two specific types of blood cancers.
“A customized panel of biomarker tests for Acute Myeloid Leukaemia (AML), an aggressive blood cancer and Cholangiocarcinoma (CCA), a rare bile duct cancer, is launched across India at subsidised rates making these advanced diagnostics more affordable and accessible,” a note from Servier said, adding that the panel will be available to healthcare professionals across private and government sectors. “Specifically, IDH1 and IDH2 mutation testing for AML and CCA, will be available free of cost for the government sector,” it said.
The biomarker testing initiative aims to address “access to quality molecular testing which remains largely concentrated to a small subset of Indian population, majorly in urban centres, leaving many patients without timely and accurate diagnosis,” the company said.
Aurelien Breton, Managing Director, Servier India, said, “At Servier, we believe that access to timely and precise diagnosis should never depend on where a patient lives or what they can afford. In cancers such as AML and CCA, early molecular testing may support timely and informed treatment decisions positively impacting survival rates, yet far too many patients in India are still diagnosed too late.”
Pratima Tripathi, Commercial Director (Oncology), Servier India, “Precision oncology begins with precision diagnosis. Identifying key genetic mutations is essential in guiding treatment decisions for both AML and Cholangiocarcinoma, yet access to such molecular testing remains limited for many patients in India. Through this initiative, we aim to integrate advanced biomarker testing into routine oncology practice, enabling physicians to make informed, evidence-based treatment choices and ultimately improving patient outcomes.”
Aliasgar Patanwala – Market Access Lead, Servier India, added, “Real access is built through collaborative systems. This initiative is about strengthening the last-mile coordination between labs, clinicians, and patient pathways — where most delays occur.”
The biomarker testing initiative is launched under ‘Servier Care’ patient support program which offers comprehensive support to eligible patients, including financial assistance, free drug support and subsidized diagnostics, ensuring holistic care for patients throughout the treatment journey, where legally permissible, the note said.
Published on November 11, 2025